References
- Weiss KB, Sullivan SD. The health economics of asthma and rhinitis. I. Assessing the economic impact. J Allergy Clin Immunol 2001;107:3–8
- Ishizaka K, Ishizaka T. Identification of gE antibodies as a carrier of reaginic activity. J Immunol 1967;99:1187–98
- Johansson SG, Bennich H. Immunological studies of an atypical (myeloma) immunoglobulin. Immunology 1967;13:381–94
- Rabe KF. The central role of immunoglobulin-E in allergic disease. Eur Respir Rev 2001;11:147–51
- Holt PG, Macaubas C, Stumbles PA, Sly PD. The role of allergy in the development of asthma. Nature 1999;402(Suppl):B12–17
- Burrows KM, Martinez FD, Halonen M, et al. Association of asthma with serum IgE levels and skin test reactivity to allergens. N Engl J Med 1989;320:271–7
- Sherrill DL, Stein R, Halonen M, et al. Total serum IgE and its association with asthma symptoms and allergic sensitization among children. J Allergy Clin Immunol 1999;104:28–36
- Broide DH. Molecular and cellular mechanisms of allergic disease. J Allergy Clin Immunol 2001;108:S65–71
- Jardieu PM, Fick RB Jr. IgE inhibition as a therapy for allergic disease. Int Arch Allergy Immunol 1999;118:112–15
- Presta LG, Lahr SJ, Shields RL, et al. Humanization of an antibody directed against IgE. J Immunol 1993;151:2623–32
- Shields RL, Whether WR, Zioncheck K, et al. Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol 1995;107:308–12
- Presta L, Shields R, O’Connell L, et al. The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem 1994;269:26368–73
- Baniyash M, Alkalay I, Eshhar Z. Monoclonal antibodies specific to the a-subunit of the mast cell’s FceRI block IgE binding and trigger histamine release. J Immunol 1987;138:2999–3004
- Liu J, Lester P, Builder S, Shire SJ. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry 1995;34:10474–82
- Fox JA, Hotaling TE, Struble C, et al. Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. J Pharmacol Exp Ther 1996;279:1000–8
- MacGlashan DW Jr, Bochner BS, Adelman DC, et al. Down-regulation of FceRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997;158:1438–45
- Marian M, Sun YN, Sinclair DE, et al. Clinical pharmacokinetics (PK) and IgE pharmacodynamics (PD) of omalizumab, a recombinant human monoclonal antibody to IgE [Abstr]. Clin Pharmacol Ther 2001;69:P7
- Mariani G, Strober W. Immunoglobulin metabolism. In: Metzger H, ed. Fc Receptors and the Action of Antibodies. Washington, DC: American Society of Microbiology, 1990:94–177
- Ghetie V, Hubbard JG, Kim JK, et al. Abnormally short serum half-lives of IgG in b2-microblobulin-deficient mice. Eur J Immunol 1996;26:690–6
- Boulet LP, Chapman KR, Côté J, et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997;155: 1835–40
- Casale TB, Bernstein IL, Busse WW, et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997;100:110–21
- Ädelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000;106;253–9
- Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108:184–90
- Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18:254–61
- Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001;108:e36 (full text available www.pediatrics.org/cgi/content/full/108/2/e36)
- Holgate ST, Chuchalin A, Hébert J, et al. Omalizumab (Xolair®, rhumab-E25), a novel therapy for severe allergic asthma [Abstr]. Am J Respir Crit Care Med 2001;163(Suppl):A812
- Wenzel S, Bousquet J, Freeman P, Fox H. Factors predictive of response to omalizumab therapy in patients with moderate-to-severe allergic asthma [Abstr]. J Allergy Clin Immunol 2002;109(2):A458
- Djukanovic R, Wilson SJ, Kraft M, et al. Effect of treatment with anti-IgE antibody (omalizumab) on airway inflammation in mild atopic asthma. Am J Respir Crit Care Med 2003;167:A703
- Hébert J, Yang W, D’Urzo, et al. No rebound worsening after cessation of omalizumab therapy in patients with severe allergic asthma [Abstr]. Chest 2001;120(Suppl):163S